Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Lomustine (CCNU) in Veterinary Oncology: Delayed-Toxicity Safety Profile
Lomustine, also called CCNU, is an oral nitrosourea chemotherapy drug used by veterinary oncologists for selected cancers. Use in dogs and cats is generally extra-label and requires a…
Read more
Multimodal Pain Management in Canine Cancer Care
Multimodal pain management combines approaches that act at different points in the pain pathway and addresses both the tumor and its functional consequences. A plan may include prescriptions,…
Read more
Omega-3 Fatty Acid Support: Product, Dose, and Evidence Questions
Omega-3 products are nutritional supplements, not cancer treatments. EPA and DHA content, total calories, oxidation control, formulation, and quality vary widely, and evidence from one condition or diet…
Read moreMetronomic Chemotherapy: Goal, Evidence, and Handling Boundary
Metronomic therapy uses regularly scheduled cytotoxic medication in selected plans; it remains prescription hazardous-drug treatment and is not simply gentle chemotherapy.
Read moreHome Handling of Oral Chemotherapy and Patient Waste
Families need drug-specific written instructions for receiving, storing, administering, cleaning, laundering, and disposing of chemotherapy and contaminated patient waste.
Read moreGabapentin as an Adjunct in Cancer Pain Plans
Gabapentin may be one component of multimodal pain or anxiety support, but effectiveness varies and sedation, weakness, kidney function, and compounded products need review.
Read more
Medicinal Mushroom Extracts: Product-Specific Oncology Evidence
Mushroom products differ by species, extracted fraction, standardization, contaminants, and evidence; the word mushroom does not identify a tested intervention.
Read moreTurmeric and Curcumin: Bioavailability, Interaction, and Evidence Limits
Turmeric and curcumin products vary in extract, concentration, absorption enhancers, and purity, while robust canine cancer outcome evidence is lacking.
Read moreCBD and Cannabis Products in Pets With Cancer: Regulatory and Safety Boundary
FDA has not approved CBD for animal use, and product quality, THC contamination, interactions, liver effects, sedation, legal status, and cancer claims require caution.
Read moreChinese Herbal Formulas: Identification, Quality, and Evidence Review
A named traditional formula can vary by translation, ingredient, species, processing, manufacturer, and practitioner modification, so exact identification comes before benefit or safety claims.
Read more
Yunnan Baiyao-Type Hemostasis Discussion: Preclinical Evidence Is Not Bleeding Control
Yunnan Baiyao is used anecdotally in veterinary bleeding plans, but formulation opacity and limited clinical evidence do not support relying on it to prevent or stop tumor hemorrhage.
Read moreProbiotics and Synbiotics During Cancer Treatment: Strain-Specific Evidence
Probiotic effects are strain-, combination-, product-, storage-, and condition-specific, and immune compromise changes the safety conversation.
Read more